Abbott (ABT) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2025, Abbott (ABT) reported revenue of $11.14 billion, up 7.4% over the same period last year. EPS came in at $1.26, compared to $1.14 in the year-ago quarter.The reported revenue represents a surprise of +0.63% over the Zacks Consensus Estimate of $11.07 billion. With the consensus EPS estimate being $1.25, the EPS surprise was +0.8%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net sales- Diagnostics- U.S.: $811 million versus the five-analyst average estimate of $832.19 million. The reported number represents a year-over-year change of -0.1%.Net sales- Nutrition- International: $1.26 billion versus the five-analyst average estimate of $1.26 billion. The reported number represents a year-over-year change of +3.1%.Net sales- Nutrition- U.S.: $957 million versus the five-analyst average estimate of $985.2 million. The reported number represents a year-over-year change of +2.6%.Net sales- Diagnostics- International: $1.36 billion versus the five-analyst average estimate of $1.38 billion. The reported number represents a year-over-year change of -1.5%.Net sales- Established Pharmaceuticals: $1.38 billion versus $1.37 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +6.9% change.Net sales- Diagnostics: $2.17 billion versus the six-analyst average estimate of $2.22 billion. The reported number represents a year-over-year change of -1%.Net sales- Medical Devices- Diabetes Care: $1.98 billion versus $1.94 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +20.2% change.Net sales- Nutrition: $2.21 billion versus $2.24 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +2.9% change.Net sales- Medical Devices- Structural Heart- Total: $636 million compared to the $643.65 million average estimate based on five analysts. The reported number represents a change of +12.8% year over year.Net sales- Medical Devices- Heart Failure- Total: $368 million versus $350.99 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change.Net sales- Medical Devices- Electrophysiology- Total: $700 million versus the five-analyst average estimate of $671.21 million. The reported number represents a year-over-year change of +11.6%.Net sales- Medical Devices- Vascular- Total: $757 million versus $754.03 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change.View all Key Company Metrics for Abbott here>>>Shares of Abbott have returned -0.5% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks